{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:24:41Z","timestamp":1763011481120,"version":"3.45.0"},"reference-count":74,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The National Social Science Fund of China","award":["21039"],"award-info":[{"award-number":["21039"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: The COVID-19 pandemic led to an unprecedented global health and economic crisis, and vaccination emerged as a critical intervention to control the spread of the virus and mitigate its impact on health systems and economies. Despite the rapid development and deployment of vaccines, the financial commitments required for these vaccination programs are substantial, necessitating a comprehensive understanding of the associated costs to inform future public health strategies and resource allocation. Method: This analysis estimates the global, regional, and national economic costs of COVID-19 vaccination across 234 countries and regions in the period 2020\u20132023, consisting of vaccine procurement costs and administration costs. Result: As of 31 December 2023, the global costs of COVID-19 vaccination programs were estimated at USD 246.2 billion, with vaccine procurement accounting for approximately USD 140.2 billion and administration costs totaling USD 96.4 billion. Globally, a cumulative total of 136.9 billion doses of COVID-19 vaccines had been administered. Factoring in an estimated wastage rate of 10%, it is projected that approximately 150.6 billion doses were used. On a global scale, the average number of vaccine doses administered per capita was estimated at 1.73. The mean cost per capita was USD 17.70 (95% CI: USD 15.84\u201319.56) for vaccine procurement and USD 12.16 (95% CI: USD 10.29\u201314.02) for administration, resulting in a total average cost of USD 29.85 (95% CI: USD 26.33\u201333.37) per capita. Significant disparities in costs were observed across income groups and regions. High-income countries incurred a notably higher average cost per capita of USD 76.90 (95% CI: USD 72.38\u201381.41) in contrast to low-income countries, where the per capita cost was USD 7.20 (95% CI: USD 5.38\u20139.02). For middle-income countries, the average per capita costs were USD 15.02 (95% CI: USD 10.64\u201319.40) in lower-middle-income countries and USD 28.21 (95% CI: USD 23.60\u201332.83) in upper-middle-income countries. Regionally, the Americas (AMR) reported the highest total cost at USD 70.8 billion, with an average per capita cost of USD 65.23 (95% CI: USD 56.18\u201374.28). The Western Pacific Region (WPR) followed with a total cost of USD 63.9 billion and an average per capita cost of USD 31.93 (95% CI: USD 20.35\u201343.51). Conversely, the African Region (AFR) had the lowest total spending at USD 10.8 billion and a per capita cost of USD 8.85 (95% CI: USD 5.34\u201312.37), reflecting both lower vaccine procurement and administration costs. The European Region (EUR) recorded a high average per capita cost of USD 53.36 (95% CI: USD 46.79\u201359.94), with procurement costs at USD 31.28 (95% CI: USD 27.41\u201335.14) and administration costs of USD 22.09 (95% CI: USD 19.31\u201324.87). Conclusions: The global rollout of COVID-19 vaccination revealed substantial variation in cost structures across income groups. Procurement costs imposed greater burdens on low- and lower-middle-income countries, whereas delivery and administration costs dominated in higher-income settings. These disparities highlight persistent fiscal inequities and emphasize the need for stronger international coordination and cost transparency to enhance equity, efficiency, and preparedness in future vaccination efforts.<\/jats:p>","DOI":"10.3390\/vaccines13111153","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:44:55Z","timestamp":1762865095000},"page":"1153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating the Global, Regional, and National Economic Costs of COVID-19 Vaccination During the COVID-19 Pandemic"],"prefix":"10.3390","volume":"13","author":[{"given":"Yansheng","family":"Chen","sequence":"first","affiliation":[{"name":"School of Public Health, Peking University, Beijing 100191, China"},{"name":"China Center for Health Development Studies, Peking University, Beijing 100191, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haonan","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Public Health, Peking University, Beijing 100191, China"},{"name":"China Center for Health Development Studies, Peking University, Beijing 100191, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaofan","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Public Health, Peking University, Beijing 100191, China"},{"name":"China Center for Health Development Studies, Peking University, Beijing 100191, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Fang","sequence":"additional","affiliation":[{"name":"China Center for Health Development Studies, Peking University, Beijing 100191, China"},{"name":"Peking University Health Science Center-Chinese Center for Disease Control and Prevention Joint Center for Vaccine Economics, Beijing 100191, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"ref_1","unstructured":"WHO (2024, March 30). WHO COVID-19 Dashboard Data. Available online: https:\/\/data.who.int\/dashboards\/covid19\/data."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","article-title":"Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis","volume":"114","author":"Zheng","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/jebm.12525","article-title":"Cost-effectiveness of COVID-19 vaccination: A systematic review","volume":"16","author":"Fu","year":"2023","journal-title":"J. Evid. Based Med."},{"key":"ref_4","unstructured":"WHO (2024, March 30). COVID-19 Vaccine Tracker and Landscape. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_5","unstructured":"WHO (2024, October 01). Interim Statement on COVID-19 Vaccination for Children. Available online: https:\/\/www.who.int\/news\/item\/11-08-2022-interim-statement-on-covid-19-vaccination-for-children."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Orangi, S., Kairu, A., Ngatia, A., Ojal, J., and Barasa, E. (2022). Examining the unit costs of COVID-19 vaccine delivery in Kenya. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-07864-z"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Nguyen, V.M., Moi, F., Boonstoppel, L., Duong, H.T., Vien, C.C., and Van Hoang, M. (2024). The cost of delivering COVID-19 vaccines in Vietnam. BMC Health Serv. Res., 24.","DOI":"10.1186\/s12913-024-11202-w"},{"key":"ref_8","unstructured":"WHO (2024, October 01). Costs of Delivering COVID-19 Vaccine in 92 AMC Countries. Available online: https:\/\/www.who.int\/publications\/m\/item\/costs-of-delivering-covid-19-vaccine-in-92-amc-countries."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.vaccine.2018.04.008","article-title":"Routine immunization services costs and financing in China, 2015","volume":"36","author":"Yu","year":"2018","journal-title":"Vaccine"},{"key":"ref_10","unstructured":"UN (2024, October 01). World Population Prospects (2024)\u2014Processed by Our World in Data. \u201cPopulation, Total\u2014UN WPP\u201d [Dataset]. Available online: https:\/\/ourworldindata.org\/grapher\/population-unwpp."},{"key":"ref_11","unstructured":"The World Bank (2024, October 01). World Bank Country and Lending Groups. Available online: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"key":"ref_12","unstructured":"WHO (2024, October 01). Countries. Available online: https:\/\/www.who.int\/countries\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat. Hum. Behav."},{"key":"ref_14","unstructured":"Africa CDC (2024, October 01). COVID-19 Vaccination. Available online: https:\/\/africacdc.org\/covid-19\/covid-19-vaccination\/."},{"key":"ref_15","unstructured":"PAHO (2024, October 01). COVID-19 Vaccine Doses Administered in the Americas. Available online: https:\/\/ais.paho.org\/imm\/IM_DosisAdmin-Vacunacion.asp."},{"key":"ref_16","unstructured":"US Department of STATE (2024, September 30). COVID-19 Vaccine Donations, Available online: https:\/\/2021-2025.state.gov\/covid-19-vaccine-deliveries\/?safe=1."},{"key":"ref_17","unstructured":"KFF (2024, September 30). U.S. International COVID-19 Vaccine Donations Tracker. Available online: https:\/\/www.kff.org\/covid-19\/u-s-international-covid-19-vaccine-donations-tracker\/."},{"key":"ref_18","unstructured":"BridgeBeijing (2024, September 30). China COVID-19 Vaccine Tracker. Available online: https:\/\/bridgebeijing.com\/our-publications\/our-publications-1\/china-covid-19-vaccines-tracker\/."},{"key":"ref_19","unstructured":"WHO (2024, October 01). 2023 WHO Global Vaccine Market Report. Available online: https:\/\/www.who.int\/publications\/i\/item\/B09022."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejor.2018.01.015","article-title":"Literature review: The vaccine supply chain","volume":"268","author":"Duijzer","year":"2018","journal-title":"Eur. J. Oper. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1016\/j.vaccine.2021.05.019","article-title":"Systematic review of the costs for vaccinators to reach vaccination sites: Incremental costs of reaching hard-to-reach populations","volume":"39","author":"Ozawa","year":"2021","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Uddin, M.N., and Roni, M.A. (2021). Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9091033"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1377\/hlthaff.2022.00343","article-title":"Financing And Funding Gap For 16 Vaccines Across 94 Low- and Middle-Income Countries, 2011\u20132030","volume":"42","author":"Sriudomporn","year":"2023","journal-title":"Health Aff."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1377\/hlthaff.2011.0332","article-title":"An Analysis Of How The GAVI Alliance And Low- And Middle-Income Countries Can Share Costs Of New Vaccines","volume":"30","author":"Saxenian","year":"2011","journal-title":"Health Aff."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mustafa Diab, M., Zimmerman, A., Dixit, S., Mao, W., Bharali, I., Kristoffersen, A., Yamey, G., and Ogbuoji, O. (2021). The Cost of Procuring and Delivering COVID-19 Vaccines in Low- and Middle-Income Countries: A Model of Projected Resource Needs. SSRN Electron. J.","DOI":"10.2139\/ssrn.3824690"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e210105","DOI":"10.1001\/jamahealthforum.2021.0105","article-title":"Allocating COVID-19 Vaccines Globally: An Urgent Need","volume":"2","year":"2021","journal-title":"JAMA Health Forum"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e006598","DOI":"10.1136\/bmjgh-2021-006598","article-title":"We need people\u2019s WHO to solve vaccine inequity, and we need it now","volume":"6","author":"Kim","year":"2021","journal-title":"BMJ Glob. Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1377\/hlthaff.2015.1080","article-title":"Vaccine Assistance To Low- and Middle-Income Countries Increased To $3.6 Billion In 2014","volume":"35","author":"Haakenstad","year":"2016","journal-title":"Health Aff."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2471\/BLT.20.273375","article-title":"Vaccine manufacturing capacity in low- and middle-income countries","volume":"99","author":"Khan","year":"2021","journal-title":"Bull. World Health Organ."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2471\/BLT.21.287381","article-title":"Addressing production gaps for vaccines in African countries","volume":"99","author":"Tomson","year":"2021","journal-title":"Bull. World Health Organ."},{"key":"ref_31","first-page":"612","article-title":"High-Income Countries Have Secured the Bulk of COVID-19 Vaccines","volume":"325","author":"Kuehn","year":"2021","journal-title":"JAMA"},{"key":"ref_32","first-page":"983","article-title":"The Real Cost of the US Health Care System","volume":"319","author":"Emanuel","year":"2018","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/PHH.0000000000001561","article-title":"Assessment of the Costs of Implementing COVID-19 Vaccination Clinics in 34 Sites, United States, March 2021","volume":"28","author":"Yarnoff","year":"2022","journal-title":"J. Public Health Manag. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Liu, Y., Procter, S.R., Pearson, C.A.B., Montero, A.M., Torres-Rueda, S., Asfaw, E., Uzochukwu, B., Drake, T., Bergren, E., and Eggo, R.M. (2023). Assessing the impacts of COVID-19 vaccination programme\u2019s timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries. BMC Med., 21.","DOI":"10.1186\/s12916-023-02784-z"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2020.12603","article-title":"Persistent symptoms in patients after acute COVID-19","volume":"324","author":"Bernabei","year":"2020","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.dsx.2021.04.007","article-title":"Long COVID: An overview","volume":"15","author":"Raveendran","year":"2021","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/14760584.2023.2157817","article-title":"Estimated global public health and economic impact of COVID-19 vaccines in the pre-omicron era using real-world empirical data","volume":"22","author":"Yang","year":"2023","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s43546-022-00258-7","article-title":"The COVID-19 vaccine rollout and labor market recovery in the U.S: A note","volume":"2","author":"Ogundari","year":"2022","journal-title":"SN Bus. Econ."},{"key":"ref_39","first-page":"68","article-title":"Study on decomposition and countermeasures of the economic impact of COVID-19","volume":"38","author":"Zhang","year":"2021","journal-title":"Stat. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41937-021-00082-0","article-title":"The effects of COVID-19 vaccines on economic activity","volume":"158","author":"Deb","year":"2022","journal-title":"Swiss J. Econ. Stat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/13696998.2022.2026118","article-title":"The societal economic value of COVID-19 vaccines in the United States","volume":"25","author":"Kirson","year":"2022","journal-title":"J. Med. Econ."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zhang, H., Patenaude, B., Ma, C., and Fang, H. (2023). Vaccine pricing strategies in China. BMJ Glob. Health, 8.","DOI":"10.1136\/bmjgh-2022-011405"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12962-023-00430-2","article-title":"Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: An analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru","volume":"21","author":"Augustovski","year":"2023","journal-title":"Cost Eff. Resour. Alloc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e2243127","DOI":"10.1001\/jamanetworkopen.2022.43127","article-title":"Return on Investment of the COVID-19 Vaccination Campaign in New York City","volume":"5","author":"Sah","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_45","unstructured":"Government of China (2024, October 01). The Expenditure on COVID-19 Vaccines in China Exceeds 120 Billion Yuan, Available online: https:\/\/www.gov.cn\/xinwen\/2022-04\/03\/content_5683325.htm."},{"key":"ref_46","unstructured":"The People\u2019s Goverenment of Jiangyong County (2024, October 01). Jiangyong County Center for Disease Control and Prevention Performance Evaluation Report on the Special Fund Project for COVID-19 Vaccination in 2021, Available online: http:\/\/www.jiangyong.gov.cn\/jiangyong\/jxpj\/202212\/369ee575d22f465fa467c1f819949bca.shtml."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Joshi, K., Scholz, S., Maschio, M., Kohli, M., Lee, A., Fust, K., Ultsch, B., Van de Velde, N., and Beck, E. (2023). Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany. medRxiv.","DOI":"10.1101\/2023.10.09.23296505"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.vaccine.2022.01.036","article-title":"Estimating the cost of COVID-19 vaccine deployment and introduction in Ghana using the CVIC tool","volume":"40","author":"Nonvignon","year":"2022","journal-title":"Vaccine"},{"key":"ref_49","first-page":"109","article-title":"Economic evaluations of inactivated COVID-19 vaccines in six Western Pacific and South East Asian countries and regions: A modeling study","volume":"7","author":"Jiang","year":"2022","journal-title":"Infect. Dis. Model."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Nurchis, M.C., Lontano, A., Pascucci, D., Sapienza, M., Marziali, E., Castrini, F., Messina, R., Regazzi, L., Causio, F.A., and Di Pilla, A. (2022). COVID-19 Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Cost-Benefit Analysis. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19137848"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/14760584.2024.2323133","article-title":"Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan","volume":"23","author":"Nagano","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"125988","DOI":"10.1016\/j.vaccine.2024.05.036","article-title":"A cost-effectiveness analysis of South Africa\u2019s COVID-19 vaccination programme","volume":"42","author":"Edoka","year":"2024","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"L\u00f3pez, F., Catal\u00e0, M., Prats, C., Estrada, O., Oliva, I., Prat, N., Isnard, M., Vall\u00e8s, R., Vilar, M., and Clotet, B. (2021). A Cost-Benefit Analysis of COVID-19 Vaccination in Catalonia. Vaccines, 10.","DOI":"10.20944\/preprints202111.0435.v1"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/13696998.2023.2193067","article-title":"Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4\/BA.5) in the United States","volume":"26","author":"Marczell","year":"2023","journal-title":"J. Med. Econ."},{"key":"ref_55","unstructured":"Meredith, S. (2024, October 01). Why Cuba\u2019s Extraordinary Covid Vaccine Success Could Provide the Best Hope for Low-Income Countries. Available online: https:\/\/www.cnbc.com\/2022\/01\/13\/why-cubas-extraordinary-covid-vaccine-success-could-provide-the-best-hope-for-the-global-south.html."},{"key":"ref_56","unstructured":"World Health Organization (WHO) (2019). MI4A Vaccine Purchase Data for Countries, World Health Organization."},{"key":"ref_57","unstructured":"PTI (2024, October 01). Biological E Reduces Price of COVID-19 Vaccine Corbevax to Rs 250. Available online: https:\/\/www.thenewsminute.com\/news\/biological-e-reduces-price-covid-19-vaccine-corbevax-rs-250-164018."},{"key":"ref_58","unstructured":"Bora, S. (2024, October 01). Here\u2019s the List of Prices of All COVID-19 Vaccines Authorised Around the World. Available online: https:\/\/www.shethepeople.tv\/coronavirus\/covid-vaccine-prices-india-and-the-world\/."},{"key":"ref_59","unstructured":"Drugs.com (2024, October 01). Novavax COVID-19 Vaccine Prices, Coupons, Copay Cards & Patient Assistance. Available online: https:\/\/www.drugs.com\/price-guide\/novavax-covid-19-vaccine."},{"key":"ref_60","unstructured":"BMJ (2024, October 01). What Do We Know About China\u2019s COVID-19 Vaccines?. Available online: https:\/\/www.bmj.com\/content\/373\/bmj.n912\/rr-0."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.56101\/rimj.v3i2.95","article-title":"COVID-19 Vaccines Coverage in Afghanistan: A Descriptive Analysis of Secondary Data from DHIS2","volume":"3","author":"Matin","year":"2023","journal-title":"Razi Int. Med. J."},{"key":"ref_62","unstructured":"Reuters (2024, October 01). Albania Gets 192,000 Doses of Chinese Sinovac Vaccine. Available online: https:\/\/www.reuters.com\/article\/us-health-coronavirus-albania-vaccines-idUSKBN2BH2N9\/."},{"key":"ref_63","unstructured":"Albanian Government Council of Ministers (2024, October 01). 500,000 Pfizer\u2019s COVID Vaccine Doses Secured, Available online: https:\/\/kryeministria.al\/en\/newsroom\/sigurohen-500-mije-doza-te-vaksines-pfizer\/."},{"key":"ref_64","unstructured":"Albanian Daily News (2024, October 01). 50000 Russian Vaccine Doses to Come to Albania Next Week. Available online: https:\/\/albaniandailynews.com\/news\/50-000-russian-vaccine-doses-to-come-to-albania-next-week."},{"key":"ref_65","unstructured":"Agjencia Telegrafike Shqiptare (2024, October 01). Mb\u00ebrrin n\u00eb Rinas partia e par\u00eb e 22 230 dozave Pfizer, q\u00eb do t\u00eb l\u00ebvrohen deri n\u00eb 20 prill, Available online: https:\/\/ata.gov.al\/2021\/04\/05\/mberrin-ne-rinas-partia-e-pare-e-22-230-dozave-pfizer-qe-do-te-levrohen-deri-ne-20-prill\/."},{"key":"ref_66","unstructured":"ABCNEWS (2024, October 01). Albania Receives 10,000 Doses of Russian Vaccine \u201cSputnik V\u201d. Available online: https:\/\/abcnews.al\/albania-receives-10000-doses-of-russian-vaccine-sputnik-v\/."},{"key":"ref_67","unstructured":"A2NEWS (2024, October 01). Albania Receives 145,000 Pfizer Vaccines, Rama: Politicians and Analysts Should Not Jump to Conclusions. Available online: https:\/\/web.archive.org\/web\/20210420144557\/https:\/\/english.a2news.com\/2021\/04\/20\/albania-receives-145000-pfizer-vaccines-rama-politicians-and-analysts-should-not-jump-to-conclusions\/."},{"key":"ref_68","unstructured":"A2NEWS (2024, October 01). Albania Received 208,000 New Doses of COVID-19 Vaccines. Available online: https:\/\/web.archive.org\/web\/20210419171328\/https:\/\/english.a2news.com\/2021\/04\/19\/albania-received-208000-new-doses-of-covid-19-vaccines\/."},{"key":"ref_69","unstructured":"Ting, I., S, K., and Palmer, A. (2024, October 01). Tracking Australia\u2019s COVID Vaccine Rollout Numbers. Available online: https:\/\/www.abc.net.au\/news\/2021-03-02\/charting-australias-covid-vaccine-rollout\/13197518."},{"key":"ref_70","unstructured":"Worthington, B. (2024, October 01). Australia Secures Additional Pfizer Vaccine Following AstraZeneca Concerns. Available online: https:\/\/www.abc.net.au\/news\/2021-04-09\/national-cabinet-astrazeneca-covid-vaccine-clots-rollout\/100058440."},{"key":"ref_71","unstructured":"9NEWS (2024, October 01). Australian Government Secures 85 Million Pfizer Booster Shots for 2022 and 2023. Available online: https:\/\/www.9news.com.au\/national\/coronavirus-vaccine-rollout-85-million-pfizer-booster-doses-to-arrive-february-2022\/2ec88b59-aa76-4a26-a1cb-4bdf997888ea."},{"key":"ref_72","unstructured":"9NEWS (2024, October 01). Second Shipment of Pfizer COVID-19 Arrives in Australia, Boosting National Supply. Available online: https:\/\/www.9news.com.au\/national\/coronavirus-vaccine-second-pfizer-shipment-arrives-in-australia-boosting-rollout\/b9f60f8e-7eed-4e1d-ae70-b96478fc7352."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"92","DOI":"10.35772\/ghm.2023.01002","article-title":"COVID-19 Vaccination Program in Cambodia: Achievements and Remaining Challenges","volume":"5","author":"Nozaki","year":"2023","journal-title":"Glob Health Med"},{"key":"ref_74","unstructured":"VACCINATE INDIA (2024, October 01). VACCINATE INDIA DASHBOARD. Available online: https:\/\/vaccinate-india.in\/dashboard."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T05:21:18Z","timestamp":1763011278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":74,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["vaccines13111153"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13111153","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}